Organon, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on the stock and has a $10.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Terence Flynn has given his Hold rating due to a combination of factors impacting Organon. The recent resignation of CEO Kevin Ali following an investigation into improper purchasing practices related to Nexplanon has created uncertainty around the company’s leadership. The investigation revealed that certain U.S. wholesalers were encouraged to overpurchase Nexplanon to meet guidance, which, while not significant in terms of revenue, raised concerns about the company’s sales practices.
Despite no financial restatement being required, the company’s board is taking steps to improve financial controls. The interim CEO appointment and the ongoing search for a permanent CEO add to the uncertainty. Additionally, a surprising dividend cut earlier this year has contributed to the cautious outlook. These factors collectively suggest a period of uncertainty for Organon, justifying the Hold rating as investors await more clarity on the company’s strategic direction.
In another report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $7.00 price target.